AFIAS is the platform of choice that uses blood or swabs to detect the presence of both Covid-19 IgG/IgM antibodies and Covid-19 Ag in suspected patients at the point of need, when time matters and a quantitative or semi-quantitative measurement is required. Ideal for the combo usage with VitaPCR to generate a unique bundle capable of providing a detailed picture of the patient status of illness in every decentralised setting, including those in hard to reach areas.

• The AFIAS platform is scalable: it consists of two devices: AFIAS 1, which can handle one test at a time, and AFIAS 6, which allows 6 samples to be examined at the same time. 
• The same platform can also be used to perform both serological antibody tests, detecting the presence and measuring the quantity of IgM and IgG antibodies in a patient’s blood sample and for checking the presence of the antigen, namely a specific viral protein.
• The cartridge is fully automated and requires little nor work from an operator (lab-on-a-cartridge) 

AFIAS COVID-19 Ag is an automatic fluorescence Immunoassay (FIA) for the qualitative/semi-quantitative detection of novel corona virus (eg, SARS-CoV-2, 2019-nCoV) in human nasopharyngeal swab. It is useful as an aid in management and monitoring of SARS-CoV-2 infection (COVID-19).

AFIAS COVID-19 Ab is an automatic fluorescence Immunoassay(FIA) for the qualitative/semi-quantitative determination of IgG/IgM antibodies against 'Novel Coronavirus' in human whole blood/serum/plasma. It is helpful as an aid in the screening of early mild, asymptomatic or acute patients for identification of 'Novel Coronavirus (eg, SARS, 2019-nCoV)' infection with high sensitivity. Finger blood (peripheral blood; whole blood) using the unique 'all-in-one' tube, allows the patient's pain to blood collection to be relatively low and suitable for large-scale screening in the field.